来凯医药有限公司（以下简称“来凯医药”，股份代号：2105）于2026年2月5日发布截至2026年1月31日止月份的股份变动月报表。公告显示，公司本月注册股本及已发行股份总数均保持不变。
来凯医药本月注册股本仍为5,000,000,000股普通股，面值每股0.00001美元，注册股本总额维持在50,000美元。已发行股份数亦维持于446,466,350股，未见新增发行、购回或注销股份，亦无库存股持有或转让变动。
公司于报告期内的股权激励计划并未导致任何新股发行或库存股变动。首次公开发售前购股权计划（2018年4月11日采纳）与首次公开发售后购股权计划（2023年6月9日采纳）均无新增行使记录。截至月末，公司亦确认满足香港联交所对最低公众持股量的规定。
公告显示，本次月度股份变动事项符合上市规则及相关法律规定，并已获得董事会正式授权审批。该报告由公司联席公司秘书柯晨煜签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.